BioXcel Therapeutics (BTAI) EBITDA (2017 - 2026)

BioXcel Therapeutics' EBITDA history runs 10 years deep, the most recent figure standing at -$10.2 million for Q1 2026.

• On a quarterly basis, EBITDA fell 1.23% year-over-year to -$10.2 million in Q1 2026; TTM through Mar 2026 was -$50.6 million, a 4.88% increase from a year earlier, with the FY2025 full-year figure at -$50.5 million, up 24.96% from the prior year.
• EBITDA improved to -$10.2 million in Q1 2026 per BTAI's latest filing, from -$10.3 million in the prior quarter.
• Across five years, EBITDA topped out at -$10.1 million in Q1 2025 and bottomed at -$52.9 million in Q4 2022.
• The 5-year median for EBITDA is -$19.9 million (2023), against an average of -$27.0 million.
• Across the five-year window, EBITDA plunged 102.42% in 2022 and jumped 68.34% in 2024, its largest moves.
• Year by year, EBITDA stood at -$52.9 million in 2022, then jumped by 62.42% to -$19.9 million in 2023, then soared by 47.21% to -$10.5 million in 2024, then climbed by 2.01% to -$10.3 million in 2025, then grew by 0.57% to -$10.2 million in 2026.
• Per Business Quant, the three latest BTAI EBITDA figures stand at -$10.2 million (Q1 2026), -$10.3 million (Q4 2025), and -$14.2 million (Q3 2025).